.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX16_OportuzumabMonatox.OportuzumabMonatox .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX16_OportuzumabMonatox.OportuzumabMonatox| name: | OportuzumabMonatox |
| ATC code: | L01FX16 | route: | intravesical |
| n-compartments | 1 |
Oportuzumab monatox is a recombinant fusion protein consisting of a humanized monoclonal antibody targeting EpCAM (epithelial cell adhesion molecule) fused to a truncated Pseudomonas exotoxin A. It is developed as an anti-cancer agent, specifically for the treatment of non-muscle invasive bladder cancer (NMIBC), targeting EpCAM-expressing tumor cells. The drug is not currently approved for use by regulatory agencies.
No peer-reviewed publication available reporting specific pharmacokinetic parameters for oportuzumab monatox in human populations as of the latest literature review (up to June 2024).